Schizophrenia
Conditions
Keywords
Schizophrenia
Brief summary
A study to determine the maximum tolerated dose of an investigational drug in subjects with schizophrenia
Detailed description
This is a single-center, randomized, double-blind, placebo-controlled, inpatient, single ascending dose (SAD) study designed to evaluate the safety, tolerability, and PK of lurasidone injectable suspension in subjects with schizophrenia. This study will determine the minimum intolerable dose (MID), the maximum tolerated dose (MTD) of lurasidone injectable suspension, and characterize the PK profiles of lurasidone and its metabolites in serum (ID-14283, ID-14326, ID-11614, ID-20219, and ID-20220) and urine (ID-14283, ID-14326, and ID-11614) in this subject population. The potential effects of gender on the PK of lurasidone injectable suspension and its metabolites will also be evaluated when applicable.
Interventions
DRUGDSP-1349M
DSP-1349M injectable
DRUGplacebo
placebo injection
Sponsors
Sumitomo Pharma America, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Subject has capacity; is willing and able to provide written consent for use and disclosure of protected health information per requirements of 45CFR164.508 (Health Insurance Portability and Accountability Act; HIPAA) prior to initiating any study procedure after being informed of the nature of the study, in the opinion of the study staff and PI. 2\. Subject is male or female 18 to 65 years of age, inclusive. 3. Subject has a diagnosis of schizophrenia as per DSM-IV-TR criteria, which in the opinion of the Investigator has been clinically stable for the past 6 months. 4\. Subject has a Body Mass Index (BMI) greater than or equal to 19.5 and less than or equal to 38 kg/m2. 5\. Subject does not have clinically relevant abnormal laboratory values per Investigator discretion. 6\. Subject does not have clinically relevant findings from vital signs measurements per Investigator discretion. 7\. Female subject is eligible to enter and participate in the study if she is of: a. Non-childbearing potential (ie, physiologically incapable of becoming pregnant, including any female who is pre-menarchal or post-menopausal); * Postmenopausal females defined as being amenorrheic for greater than 2 years (or confirmed by FSH level) with an appropriate clinical profile. * Women who have not been confirmed as postmenopausal should be advised to use contraception as outlined below. * Women who have had a hysterectomy, bilateral oophorectomy or bilateral salpingectomy (as determined by subject's medical history). b. Child-bearing potential (all females ≤ 65 years of age), has a negative pregnancy test at screening and agrees to satisfy one of the following requirements: * Complete abstinence from intercourse (as part of an abstinent lifestyle) a minimum of 2 months prior to administration of the first dose of study drug, throughout the Treatment Period, and for a minimum of 3 months after completion or premature discontinuation from the study drug; or, * Established use of highly effective methods of contraception from 1 month prior to administration of the first dose of study drug, during the Treatment Period, and 60 days after completion or premature discontinuation from the study drug. * Because of the unacceptable failure rate of barrier (chemical and/or physical) methods, the barrier method of contraception must only be used in combination with a highly effective method. Post-coital methods of contraception are not permitted. 8\. Male subjects with partners of child bearing potential must be practicing abstinence, part of an abstinent life style or using protocol-specified methods of birth control throughout the study and for 30 days after completion or premature discontinuation from the study drug. 9\. Subject is able and willing to remain off of prior antipsychotic medication until the protocol-specified restabilization period. 10\. Subject has a stable living arrangement for at least 3 months prior to Day -12 and agrees to return to a similar living arrangement after discharge. Such subjects remain eligible to participate in this protocol with approval from the PI. Chronically homeless subjects should not be enrolled. The Medical Monitor should be consulted for individual cases as
Exclusion criteria
1. Subject had an acute exacerbation of psychiatric symptoms requiring change in antipsychotic medication (with reference to drug or dose) within 3 months (90 days) before screening. 2. Subject has known or suspected carcinoma. 3. Subject has known presence or history of renal or hepatic insufficiency. 4. Subject has significant disease(s) or clinically significant finding(s) on physical examination determined by the Investigator to pose a health concern to the subject while on study. 5. Subject has a history or presence of clinically significant abnormal ECG (based on ECG central overread report) that may jeopardize the subject's safety to participate in this study, or a screening 12-lead ECG demonstrating any one of the following: heart rate (HR) \> 100 bpm, QRS \> 120 msec, QTcF \> 450 msec, or PR \> 220 msec. 6. Subject has known history of a severe reaction to a previous antipsychotic (in the Investigator's opinion), including up to 80 mg/day of oral lurasidone. 7. Subject has a history of drug-dependence as per DSM-IV-TR criteria during the six month period immediately prior to study entry. 8. Subject has known or suspected excessive alcohol consumption, (exceeding more than 4 drinks on any single day or more than 14 drinks per week; 1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the screening visit or a positive urine alcohol test at screening. 9. Subject answers yes to Suicidal Ideation Items 4 or 5 on the C-SSRS at screening (in the past 1 month \[30 days\]) or at any point prior to randomization or history of suicidal behavior within the last two years. 10. Subject has significant orthostatic hypotension at screening (ie, a drop in systolic blood pressure of 30 mmHg or more and/or drop in diastolic blood pressure of 20 mmHg or more on standing). 11. Subject has presence or history (within the last year) of a medical or surgical condition that might interfere with the absorption, metabolism, or excretion of administered Lurasidone injectable suspension. 12. Subject has a history of epilepsy or risk of having seizures. 13. Subject has a positive urine alcohol at screening or on Day -12. 14. Subject has positive test results within 28 days prior to the start of the study for: 1. Human immunodeficiency virus (HIV). 2. Hepatitis B surface antigen and Hepatitis C antibody. 3. Urine drug test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines, methadone, or other drugs of abuse). However, a positive test for benzodiazepines may not result in exclusion of subjects if the Investigator determines that the use of a prescription benzodiazepine is appropriate. 4. Serum β-human chorionic gonadotropin (HCG) consistent with pregnancy (females only). 15. Subject has used of any inhibitor or inducer of CYP3A4 taken within 28 days prior to drug administration and until discharge. 16. Subject has have used of concomitant medications that prolong the QT/QTc interval within 28 days prior to Day -12 through follow-up. 17. Subject has received depot neuroleptics unless the last injection was at least one treatment cycle before Day -12. 18. Subject has poor peripheral venous access or does not tolerate venipuncture that would cause difficulty for collecting blood samples. 19. Subject has experienced significant blood loss (≥ 473 mL) or donated blood within 30 days prior to screening, or intends to donate plasma or blood or undergo elective surgery during study participation or within 30 days after the last study visit. 20. Subject has a prolactin concentration greater than or equal to 200 ng/mL at screening. 21. Subject is unwilling to abstain from vigorous exercise from Day -12 until study discharge. 22. Subjects has a significant risk of violent behavior or a significant risk of suicidal behavior based on history or in the PI's judgment OR is considered by the Investigator to be at imminent risk of suicide or injury to self, others, or property. 23. Subject has a history of allergic reaction (clinically relevant history of drug hypersensitivity) or has a known or suspected sensitivity to any substance that is contained in the study drug or to Polysorbate 80, sodium chloride, or sodium phosphate. 24. Subject requires treatment with a drug that consistently prolongs the QTc interval. 25. Subject is currently participating, or has participated in a study with an investigational or marketed compound or device within 30 days prior to signing the informed consent, or Protocol D1052024, Version 2.00 Lurasidone Injectable Suspension Confidential and Proprietary 36 13 June 2018 has participated in 3 or more studies within 18 months prior to signing the informed consent. 26. Subject is a staff member or the relative of a staff member. 27. Subject, in the Investigator's opinion, is unsuitable in any other way to participate in the study. 28. Subject is unable or unwilling to comply with study instructions, procedures or restrictions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Day 61 | Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation |
| Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | Day 61 | The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration |
| Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | Day 61 | The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lurasidone 30 mg Lurasidone injection suspension 30 mg | 6 |
| Lurasidone 75 mg Lurasidone injection suspension 75 mg | 6 |
| Lurasidone 150 mg Lurasidone injection suspension 150 mg | 6 |
| Lurasidone 300 mg Lurasidone injection suspension 300 mg | 6 |
| Lurasidone 450 mg Lurasidone injection suspension 450 mg | 6 |
| Placebo Placebo Injection | 10 |
| Total | 40 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | OTHER (LACK OF EFFICACY) | 1 | 0 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Total | Placebo | Lurasidone 450 mg | Lurasidone 30 mg | Lurasidone 300 mg | Lurasidone 150 mg | Lurasidone 75 mg |
|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 40 Participants | 10 Participants | 6 Participants | 6 Participants | 6 Participants | 6 Participants | 6 Participants |
| Age, Continuous | 47.4 Years STANDARD_DEVIATION 10.23 | 45.7 Years STANDARD_DEVIATION 10.25 | 52.8 Years STANDARD_DEVIATION 11.81 | 43.7 Years STANDARD_DEVIATION 13.29 | 46.2 Years STANDARD_DEVIATION 9.72 | 52 Years STANDARD_DEVIATION 4.47 | 45 Years STANDARD_DEVIATION 10.22 |
| Baseline Positive and Negative Syndrome Scale (PANSS) Total Score | 60.1 units on a scale STANDARD_DEVIATION 7.93 | 64.3 units on a scale STANDARD_DEVIATION 7.56 | 58.3 units on a scale STANDARD_DEVIATION 6.8 | 60.2 units on a scale STANDARD_DEVIATION 7.76 | 53.7 units on a scale STANDARD_DEVIATION 7.55 | 59.3 units on a scale STANDARD_DEVIATION 7.94 | 62 units on a scale STANDARD_DEVIATION 8.25 |
| BMI (kg/m^2) | 29.23 kg/m^2 STANDARD_DEVIATION 5.295 | 30.37 kg/m^2 STANDARD_DEVIATION 3.919 | 28.77 kg/m^2 STANDARD_DEVIATION 5.125 | 30.88 kg/m^2 STANDARD_DEVIATION 6.444 | 29.83 kg/m^2 STANDARD_DEVIATION 6.493 | 27.68 kg/m^2 STANDARD_DEVIATION 5.975 | 27.1 kg/m^2 STANDARD_DEVIATION 5.522 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 6 Participants | 2 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 34 Participants | 8 Participants | 6 Participants | 5 Participants | 4 Participants | 6 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Height (cm) | 170.8 cm STANDARD_DEVIATION 8.29 | 168.5 cm STANDARD_DEVIATION 7.07 | 174.2 cm STANDARD_DEVIATION 7.25 | 170 cm STANDARD_DEVIATION 8.83 | 166.3 cm STANDARD_DEVIATION 7.92 | 174.3 cm STANDARD_DEVIATION 10.39 | 173.2 cm STANDARD_DEVIATION 8.61 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 29 Participants | 7 Participants | 4 Participants | 5 Participants | 4 Participants | 5 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 10 Participants | 3 Participants | 2 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants |
| Sex: Female, Male Female | 15 Participants | 5 Participants | 1 Participants | 3 Participants | 2 Participants | 2 Participants | 2 Participants |
| Sex: Female, Male Male | 25 Participants | 5 Participants | 5 Participants | 3 Participants | 4 Participants | 4 Participants | 4 Participants |
| Weight (kg) | 85 kg STANDARD_DEVIATION 14.99 | 86.7 kg STANDARD_DEVIATION 15.07 | 86.8 kg STANDARD_DEVIATION 15.2 | 88.3 kg STANDARD_DEVIATION 13.53 | 82 kg STANDARD_DEVIATION 16.55 | 84.8 kg STANDARD_DEVIATION 21.84 | 80.3 kg STANDARD_DEVIATION 10.86 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 |
| other Total, other adverse events | 4 / 6 | 4 / 6 | 2 / 6 | 4 / 6 | 5 / 6 | 5 / 10 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 6 | 0 / 10 |
Outcome results
Primary
Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration
The area Under the Curve from time 0 to time of last quantifiable concentration \[AUC0-last\] for lurasidone after lurasidone injectable suspension administration
Time frame: Day 61
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Lurasidone 30 mg | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 628 ng*h/mL | Geometric Coefficient of Variation 54.7 |
| Lurasidone 75 mg | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 2000 ng*h/mL | Geometric Coefficient of Variation 6.6 |
| Lurasidone 150 mg | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 3540 ng*h/mL | Geometric Coefficient of Variation 26 |
| Lurasidone 300 mg | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 4910 ng*h/mL | Geometric Coefficient of Variation 47.9 |
| Lurasidone 450 mg | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 7490 ng*h/mL | Geometric Coefficient of Variation 32.6 |
| Placebo | Area Under the Curve From Time 0 to Time of Last Quantifiable Concentration [AUC0-last] for Lurasidone After Lurasidone Injectable Suspension Administration | 0 ng*h/mL | Geometric Coefficient of Variation 0 |
Primary
Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation
Number of subjects with any Adverse Events (AEs), serious adverse events (SAEs), and Adverse Events (AEs ) leading to study discontinuation
Time frame: Day 61
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Lurasidone 30 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Lurasidone 30 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Lurasidone 30 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 4 count of participants |
| Lurasidone 75 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Lurasidone 75 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 4 count of participants |
| Lurasidone 75 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Lurasidone 150 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Lurasidone 150 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 2 count of participants |
| Lurasidone 150 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Lurasidone 300 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Lurasidone 300 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 4 count of participants |
| Lurasidone 300 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Lurasidone 450 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Lurasidone 450 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 5 count of participants |
| Lurasidone 450 mg | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Placebo | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs leading to study discontinuation | 0 count of participants |
| Placebo | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of SAEs | 0 count of participants |
| Placebo | Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs ) Leading to Study Discontinuation | Incidence of AEs | 5 count of participants |
Primary
Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration
The maximum Serum Concentration \[Cmax\] for lurasidone after lurasidone injectable suspension administration
Time frame: Day 61
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Lurasidone 30 mg | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 1.08 ng/mL | Geometric Coefficient of Variation 65.6 |
| Lurasidone 75 mg | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 3.90 ng/mL | Geometric Coefficient of Variation 51.6 |
| Lurasidone 150 mg | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 5.08 ng/mL | Geometric Coefficient of Variation 46.5 |
| Lurasidone 300 mg | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 8.85 ng/mL | Geometric Coefficient of Variation 62.8 |
| Lurasidone 450 mg | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 9.50 ng/mL | Geometric Coefficient of Variation 48.3 |
| Placebo | Maximum Serum Concentration [Cmax] for Lurasidone After Lurasidone Injectable Suspension Administration | 0 ng/mL | Geometric Coefficient of Variation 0 |